NEW YORK, Nov. 1, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Spectrum Pharmaceuticals, Inc. SPPI based on allegations that Spectrum Pharmaceuticals has disclosed potentially materially misleading business information to the investing public.

SO WHAT: If you have purchased Spectrum Pharmaceuticals securities, you may be entitled to compensation without payment of out-of-pocket expenses or costs through a contingency fee arrangement. Law firm Rosen is preparing a class action lawsuit to recover investor losses.

WHAT TO DO NEXT: To participate in the prospective class action lawsuit, go to https://rosenlegal.com/submit-form/?case_id=9455 or call Phillip Kim, Esq. toll free at 866-767-3653 or by email pkim@rosenlegal.com or cases@rosenlegal.com for information about the Class Action.

WHAT IS THIS ABOUT: On September 22, 2022, after market close, Reuters reported that U.S. Food and Drug Administration (“FDA”) advisers “voted against Spectrum Pharmaceuticals’ recommendation” [] investigational drug to treat patients with a form of non-small cell lung cancer.” The article further reported that “[t]The FDA panel voted 9-4 against the oral drug poziotinib, citing low efficacy, high toxicity and a lack of dose optimization. The panel’s decision was in line with briefing documents released Tuesday by the drug agency, which raised concerns about the treatment’s effectiveness compared to existing drugs like Daiichi Sankyo’s [] and Enhertu by AstraZeneca.”

As a result of this news, Spectrum Pharmaceuticals stock price fell 31% on unusually high trading volume to close at $0.43 per share on September 23, 2022.

WHY ROSES LAW: We encourage investors to select qualified advisors with a track record in leadership positions. Frequently, companies that issue notices do not have comparable experience, resources, or meaningful recognition from peers. Be wise in choosing a lawyer….